Boehringer Ingelheim, one of the world’s leading research-driven pharmaceutical companies, has signed a Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH), the healthcare regulator in the Emirate. This strategic partnership is aimed at advancing scientific research and innovation, fostering cutting-edge research and development, and nurturing
With a legacy spanning 130 years as one of the world’s leading research-driven biopharmaceutical companies, Boehringer Ingelheim’s Middle East & Africa (MEA) operations are headquartered in Dubai. The company also maintains scientific offices in Egypt, Saudi Arabia, and Algeria, with its footprint extending into East Africa through Nairobi. In 2023,
Boehringer Ingelheim convened leading minds in healthcare at the Conrad Sheikh Zayed Hotel in Dubai on May 29 for the Stroke Media Academy—an exclusive, high-impact event dedicated to promoting stroke awareness and advancing holistic stroke care across the UAE and the region. The Academy brought together neurologists, healthcare professionals, and
Boehringer Ingelheim has announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments
Get notified about new articles
